Medical News
Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the KRASG12C gene mutation, if there has been progression after ≥ 1 prior line of systemic therapy. The 2-year analysis of data from the CodeBreaK 100 study published in April 2023 demonstrated the long-term benefit of sotorasib for this patient population in terms of progression-free survival (PFS) and overall survival (OS), regardless of programmed death-ligand 1 (PD-L1) receptor expression, including patients with a poor prognosis. In the Czech…
INFOGRAPHIC: Post-Induction Therapy for AML – Current Guidelines
What are the recommended therapeutic modalities for consolidation and maintenance therapy of acute myeloid leukemia (AML) in patients over 60 years of age? We present a clear therapeutic algorithm…
Oral Azacitidine After Achieving Remission in AML Improves Survival and Does Not Worsen Quality of Life
Orally administered azacitidine as maintenance therapy in patients with acute myeloid leukemia (AML) after achieving remission provides a favorable effect in terms of fatigue and improving…
Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children
Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with…
Myasthenia Gravis and Unmet Patient Needs – Data from Clinical Practice
Myasthenia gravis (MG) is a rare, chronic, disabling, unpredictable, and potentially life-threatening autoimmune neuromuscular disease. There is still a lack of sufficient data from real clinical…
Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia
Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with…
Physical Activity in Young Men with Hemophilia A
What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.
N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up
An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
Pain Management in Patients After Hip and Knee Arthroplasty – Data from Clinical Practice
Inadequate analgesia after hip and knee arthroplasty can result in delayed postoperative recovery accompanied by chronic pain. The retrospective study presented below compared the efficacy of…
Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency – Real-World Data
Even in patients with secondary immunodeficiency (SID), immunoglobulin substitution can be indicated. Intravenous (IVIG) therapy is considered effective based on studies, but subcutaneous (SCIG) therapy...
Romiplostim in ITP Treatment – Data from German Clinical Practice
Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and…
Invasive Pneumococcal Disease – Current Czech Data
The number of reported cases of invasive pneumococcal disease (IPD) returned to levels comparable to those before the COVID-19 pandemic in 2022. Regarding age-specific morbidity, the most at-risk…
Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to…
Rapid Strengthening and Long-term Stabilization – New Strategy for Sequential Treatment of Severe Osteoporosis
Osteoanabolics have long been considered a treatment modality for osteoporosis that is only considered when antiresorptive medication lacks the desired efficacy. However, their role has been shifting…
Inhibition of Sclerostin in Osteoporosis Therapy
Romosozumab, a subcutaneously administered antibody against sclerostin, is one of the most potent osteoanabolics and appears to be a highly effective modality in the treatment of postmenopausal…